

Zydus' Neshor Pharmaceuticals gets USFDA final approval for Nystatin Topical Powder

The product will be manufactured at the Neshor's manufacturing facility in the US

Ahmedabad, June 10, 2017

Neshor Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Nystatin Topical Powder USP, 100,000 units per gram. The drug will be produced at the Neshor Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA. Nystatin Topical Powder is an antifungal antibiotic used to treat skin infections caused by yeast.

The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.